News >

Crenolanib Shows Promise in AML Patients With Variant FLT3 Mutations

Angelica Welch
Published: Monday, Aug 21, 2017

Eunice Wang, MD

Eunice Wang, MD
At the 2017 European Hematology Association (EHA) Congress, Eunice Wang, MD, presented an abstract examining the biology of newly diagnosed patients with FLT3-positive acute myeloid leukemia (AML) who achieved a response to the FLT3 tyrosine kinase inhibitor (TKI) crenolanib combined with chemotherapy.

at EHA, Wang, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discussed her research and the next steps for crenolanib and other emerging FLT3 inhibitors in AML.

OncLive: Please provide an overview of the study.

Wang: This is actually a follow-up of a phase II clinical trial that was presented at the ASH 2016 Annual Meeting. In this trial, we combined crenolanib, which is a novel potent type 1 receptor TKI FLT3 with standard chemotherapy for the treatment of newly-diagnosed FLT3 mutant patients with AML.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x